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Background: SV2A, SV2B and SV2C are synaptic vesicle proteins that are structurally related to members of the
major facilitator superfamily (MFS). The function and transported substrate of the SV2 proteins is not clearly defined
although they are linked to neurotransmitters release in a presynaptic calcium concentration-dependent manner.
SV2A and SV2B exhibit broad expression in the central nervous system while SV2C appears to be more restricted in
defined areas such as striatum. SV2A knockout mice start to display generalized seizures at a late developmental
stage, around post-natal day 7 (P7), and die around P15. More recently, SV2A was demonstrated to be the
molecular target of levetiracetam, an approved anti-epileptic drug (AED). The purpose of this work was to precisely
analyze and quantify the SV2A, SV2B and SV2C expression during brain development to understand the
contribution of these proteins in brain development and their impact on epileptic seizures.
Results: First, we systematically analyzed by immunohistofluorescence, the SV2A, SV2B and SV2C expression during
mouse brain development, from embryonic day 12 (E12) to P30. This semi-quantitative approach suggests a
modulation of SV2A and SV2B expression in hippocampus around P7. This is the reason why we used various
quantitative approaches (laser microdissection of whole hippocampus followed by qRT-PCR and western blot
analysis) indicating that SV2A and SV2B expression increased between P5 and P7 and remained stable between P7
and P10. Moreover, the increase of SV2A expression in the hippocampus at P7 was mainly observed in the CA1
region while SV2B expression in this region remains stable.
Conclusions: The observed alterations of SV2A expression in hippocampus are consistent with the appearance of
seizures in SV2A−/− animals at early postnatal age and the hypothesis that SV2A absence favors epileptic seizures
around P7.
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SV2 proteins are integral transmembrane proteins ex-
pressed on synaptic dense core vesicles [1,2] but are also
found on small clear vesicles containing neurotransmitters
[3]. Cloning of the individual family members resulted in
the identification of three different isoforms, SV2A [1],
SV2B [4] and SV2C [5]. The overall homology between
the three rat isoforms is approximately 60%, with SV2A* Correspondence: Bernard.Rogister@ulg.ac.be
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distribution, and reproduction in any mediumand SV2C being more similar to each other than SV2B
[5]. SV2A is ubiquitously expressed in the central nervous
system (CNS), neuroendocrine cells [6,7] and at the
neuromuscular junction [8]. SV2B is widely expressed in
the brain [7-12] while SV2C has a more restricted distri-
bution in the CNS [5,8,11,13,14].
All SV2 isoforms are characterized by twelve transmem-
brane domains and three N-glycosilation sites in the
intravesicular loop [5,7,9]. SV2 proteins show similarities
to members of the membrane transporter family and be-
long to the major facilitator superfamily (MFS), although
the transported substrate has not been identified yet, and
the molecular function of SV2 proteins remains elusive.
However, interactions with several synaptic proteins
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with glycosilated forms of SV2A and SV2B [8,15]. More-
over, Mahrhold et al. reported that the carboxy-terminal
region of SV2C intravesicular domain mediates the Botu-
linum Neurotoxin A entry leading to its toxic effects [16].
Several groups suggested a role of SV2 proteins in the
regulation of presynaptic calcium concentration [17-19].
In contrast, other authors have reported that SV2 pro-
tein activities are not related to a change in presynaptic
calcium [20,21]. However, there is evidence linking SV2
and calcium given the demonstrated interaction of SV2
with synaptotagmin considered to be the primary cal-
cium sensor triggering calcium-dependent exocytosis
[22-24]. More recently, Wan et al. used mouse rod bipo-
lar cell preparations for direct biophysical studies meas-
uring exocytosis and presynaptic calcium concentration
in the mammalian central nervous system. In these neu-
rons, SV2B is the main SV2 isoform expressed [25,26].
As SV2B knockout (KO) mice are viable [17], Wan et al.
were able to show in rod cells from SV2B KO animals,
an elevation of Ca2+ in nerve terminal both in resting
and evoked presynaptic signals. This increase of Ca2+
concentration results in changes in synaptic vesicle dy-
namics, synaptic plasticity, and synaptic strength.
SV2A, the major isoform in the CNS has been linked
with seizures and an epileptic phenotype. SV2A KO ani-
mals are characterized by the onset of epileptic seizures in
early postnatal stage (postnatal day 7 or P7) leading to
death around P15 [17,27]. Moreover, it appears that SV2A
expression decreases during epileptogenesis and chronic-
ally epileptic animals [28-30] as well as in patients with
temporal lobe epilepsy [31,32]. The therapeutic interest of
SV2 proteins has been demonstrated with the antiepileptic
drug levetiracetam. Consecutively SV2A was identified as
the molecular target of the previously described brain-
binding site of levetiracetam [27,29]. Levetiracetam has a
unique activity profile in animal models of seizure and epi-
lepsy, favourable side-effect profile and straightforward
pharmacokinetics [33]. Furthermore, brivaracetam, a novel
antiepileptic drug (AED) with higher SV2A affinity than
levetiracetam [34], shows higher potency in several pre-
clinical models of epilepsy [35] and is currently in clinical
development [36].
In this study, we therefore systematically analyzed the
expression of all SV2 isoforms during mouse brain devel-
opment, to contribute to the understanding of their role
during development and the onset of epileptic seizures.
Results
Immunohistofluorescence (non quantitative)
A systematic analysis of immunoreactivity for SV2A,
SV2B and SV2C in several brain regions at various ages
was performed. The results obtained for the selected tel-
encephalic regions are summarized in Table 1. It waspreviously demonstrated that SV2A KO mice started to ex-
perience epileptic seizure at P7. Thus, the expression of all
SV2 isoforms was analyzed at different key developmental
steps, focusing on the developmental period around P7. In
grey matter of cortices, SV2A labelling was detectable from
embryonic day 14 and reached maximum expression at
post-natal day 9 (P9). In olfactory bulb, the signal for SV2A
reached a peak at embryonic day 16 (E16) and remained
stable in both fascicular and glomerular regions up to post-
natal day 30 (P30). In hippocampus, the labelling was
detected earlier, at embryonic day 14 (E14) but remained
localized in the hilus of dentatus gyrus (DG). The signal in
DG seemed to decrease transiently around P7 and then in-
creases in this region to reach maximum expression at
P10. In the CA1 region, low level of SV2A expression was
detectable from P7 to reach maximum levels in older ani-
mals (P30). At P7, the signal remained stable in the olfac-
tory bulbs, indicating that the decrease observed around
P7 in hippocampus was not due to technical issues related
to immunolabelling but truly reflects reduced levels of
SV2A in hilus of DG at P7. However, if we consider the
growth of these two structures (hippocampus and olfactory
bulb), one can also observe a higher expansion of the
hippocampus than the olfactory bulb around P7. In
sub-cortical nuclei and in pallidal regions, SV2A signal
appeared between embryonic day 14 and 16 (E14 and E16)
and rapidly reached high expression intensities. In these re-
gions the signal also seemed to decrease around P7 but this
decrease was less pronounced than what is observed in
hippocampus. The results for the diencephalic, mesen-
cephalic, pontic, bulbar and cerebellar regions are summa-
rized in the Additional files 1 and 2.
Quantitative confocal immunofluorescence
An apparent reduction of SV2A immunolabeling was thus
observed in hippocampus at P7, which is exactly the period
at which SV2A KO mice display epileptic seizures. In order
to understand whether reduced SV2A expression in hippo-
campus – correlating with seizure appearance – was sec-
ondary to hippocampal growth which is pronounced at
that age, we decided to quantify more precisely the expres-
sion of SV2A at post-natal day 5, 7 and 10 (Figure 1). In
addition, expression of SV2B and SV2C was studied in the
same regions (Figure 1). First, we used the fluorescence
index quantified using confocal microscopy for CA1 region
and hilus of DG. As signals for SV2A in olfactory bulbs
remained stable from P5 to P10 (Table 1), both signals in
CA1 and hilus of DG were normalized using the signal
in olfactory bulb to minimize the variation due to the
immunolabeling technique itself (Figure 2A). SV2A
immunohistofluorescence increased gradually in the
hilus of DG between post-natal days 5 (P5) and 10 (P10)
while in CA1 region, the signal for SV2A increased only
between P5 and P7. Albeit statistically significant the
Table 1 Expression levels of SV2A in various telencephalic regions at various ages (embryonic day 12, 14, 16, 18 and
post-natal day 0, 1, 6, 7, 8, 9, 10, 15 and 30)
TELENCEPHALIC REGIONS E12 E14 E16 E18 P0 P1 P6 P7 P8 P9 P10 P15 P>/= 30
Cerebral Cortex
Grey matter - ++ ++ ++ ++ ++ ++ ++ ++ +++ +++ +++ +++
White Matter - - - - - - - - - - - - -
Olfactory Bulb
Fascicular region - - + ++ ++ +++ +++ +++ +++ +++ +++ +++ +++
Glomerular region - - +++ +++ +++ +++ +++ +++ +++ +++ +++ +++ +++
Hippocampus
CA1 - + + + - - - + + + + + +++
Dentatus Gyrus - - - - - + - - - - - - +++
Hilus of dentatus gyrus (CA4) - +++ +++ ++ +++ +++ +++ + ++ ++ +++ ++ +++
Sub-cortical nuclei
Dorsal Striatum (Caudatus N. and putamen) - +++ ++ ++ +++ +++ +++ ++ ++ +++ +++ ++ +++
Ventral Striatum - - - ++ +++ ++ +++ ++ +++ +++ +++ ++ +++
Nucleus Accumbens - - +++ ++ +++ ++ ++ + ++ ++ +++ +++ +++
Septal lateral nucleus - - +++ ++ +++ +++ +++ + ++ + +++ ++ +++
Septo-fimbrial nucleus - - +++ ++ ++ +++ +++ ++ + + +++ ++ +++
Amygdala - ++ +++ +++ +++ +++ +++ + +++ +++ +++ ++ +++
Pallidum
Dorsal pallidum - - - - +++ +++ +++ ++ +++ +++ +++ ++ +++
Ventral pallidum - - - - +++ ++ +++ ++ ++ + +++ ++ +++
Magno-cellular nucleus - - +++ +++ ++ +++ +++ ++ ++ + +++ ++ ++
Posterior Pallidum (stria terminalis nucleus) - ++ +++ ++ +++ +++ +++ ++ +++ ++ +++ ++ +++
DIENCEPHALIC REGIONS
Thalamus
Polymodal sensory thalamus - - - - +++ +++ ++ + +++ + ++ ++ ++
Anterior thalamus - +++ ++ ++ ++ ++ ++ + +++ ++ ++ +++ ++
Lateral thalamus - - - ++ ++ +++ +++ ++ ++ + ++ ++ ++
Ventral thalamus - - - 1++ +++ +++ +++ ++ +++ ++ + ++ +++
Intralaminar thalamic nuclei - - - - +++ +++ +++ + ++ ++ + ++ +++
Habenula - - +++ ++ +++ +++ +++ ++ +++ ++ +++ +++ +++
Medio-dorsal thalamus - - - ++ ++ +++ ++ + +++ + ++ ++ +++
Geniculated nuclei - +++ +++ + +++ +++ +++ ++ +++ + +++ +++ +++
Hypothalamus
Periventricular region - - ++ ++ +++ +++ +++ +++ +++ + +++ +++ +++
Arcuetus nucleus - - +++ +++ +++ +++ +++ + +++ ++ +++ +++ +++
Paraventricular nucleus - - +++ +++ +++ +++ +++ ++ +++ + ++ +++ ++
Paraventricular region - - ++ +++ +++ +++ +++ + +++ + ++ ++ +++
Pre-optic nucleus - +++ ++ ++ +++ +++ +++ ++ +++ + +++ +++ +++
Supra-chiasmatic nucleus - - ++ ++ +++ +++ +++ ++ +++ ++ +++ +++ +++
Medial Hypothalamus - - - - + +++ +++ ++ +++ + ++ +++ ++
Mamillary bodies - - ++ ++ +++ +++ +++ + +++ ++ +++ ++ +++
MESENCEPHALIC REGIONS
Sensory Mesencephale
Inferior colliculus - - - +++ +++ +++ +++ +++ +++ ++ ++ +++ +++
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Table 1 Expression levels of SV2A in various telencephalic regions at various ages (embryonic day 12, 14, 16, 18 and
post-natal day 0, 1, 6, 7, 8, 9, 10, 15 and 30) (Continued)
Superior colliculus - - ++ ++ +++ +++ +++ +++ +++ ++ ++ +++ +++
Motor Mesencephale
Substantia nigra - +++ +++ +++ +++ +++ +++ ++ +++ ++ +++ + +++
Ventral tegmental area - - ++ +++ +++ +++ +++ ++ ++ +++ +++ ++ ++
Peri-aqueducal grey matter - - +++ +++ +++ ++ +++ +++ +++ +++ +++ ++ +++
Pretectal region - - +++ +++ +++ +++ +++ ++ +++ +++ +++ ++ ++
Red nucleus - - +++ ++ +++ +++ +++ ++ +++ +++ ++ ++ +++
Cuneiform nucleus - - - - +++ ++ +++ ++ +++ ++ +++ ++ ++
Common oculomotor nucleus (III) - +++ +++ +++ +++ +++ ++ +++ +++ + +++ +++ +++
Edinger Westphal nucleus - - - - +++ +++ +++ ++ +++ +++ ++ ++ +++
Behavioural Mesencephale
Pedoculo-pontic nucleus - - - - +++ +++ +++ +++ +++ +++ +++ +++ +++
Raphe nuclei - - ++ +++ +++ +++ +++ +++ ++ +++ ++ ++ +++
PONTIC REGION
Sensory pons
Lateral lemniscus nucleus - - +++ +++ +++ +++ +++ ++ +++ ++ +++ ++ +++
Superior olivary tractus nucleus - - +++ +++ +++ +++ +++ +++ +++ ++ ++ + +
Motor Pons
Motor nucleus of V - - ++ ++ +++ +++ +++ +++ +++ +++ +++ + +++
Facial nucleus (VII) - +++ +++ +++ +++ +++ +++ ++ +++ +++ ++ + +++
Dorsal tegmental nucleus - - - - +++ ++ +++ ++ ++ ++ +++ + +++
Behavioural Pons
Raphe nuclei - - ++ +++ +++ +++ +++ +++ ++ +++ ++ ++ +++
BULBAR REGION
Sensory bulb
Cochlear nucleus - - +++ +++ +++ +++ +++ ++ +++ +++ +++ +++ +++
Cuneus nucleus - - +++ +++ +++ +++ +++ +++ +++ +++ +++ ++ ++
Solitary tractus nucleus - - +++ +++ +++ +++ ++ ++ +++ ++ ++ ++ +++
Motor bulb
Ambiguus nucleus - +++ +++ +++ +++ +++ +++ ++ +++ +++ +++ ++ +++
Dorsal nucleus of vagal nerve - - +++ +++ +++ +++ +++ ++ +++ +++ +++ ++ ++
Inferior olivary complex - - ++ +++ +++ +++ +++ ++ +++ ++ ++ ++ ++
Vestibular nucleus - +++ +++ +++ +++ +++ +++ ++ +++ ++ +++ ++ +++
Hypoglosse nucleus - +++ +++ +++ +++ +++ +++ +++ +++ ++ ++ ++ +++
CEREBELLUM
Cerebellar cortex
Molecular layer - - - - +++ +++ +++ +++ +++ +++ +++ +++ +++
Purkinje cells layer - - - +++ +++ +++ +++ +++ +++ +++ +++ +++ +++
Internal granular layer - - - - - - - - - - - - -
Cerebellar nuclei
Dentatus nucleus - - - ++ +++ +++ +++ +++ +++ +++ +++ ++ ++
Fastigial nucleusl - - - +++ +++ +++ +++ +++ +++ +++ +++ +++ +++
The level of immunohistofluorescence has been evaluated based of the signal intensity in four classes : - for no labelling, +, ++ and +++ for respectively low,
medium and intense fluorescence and brightness.
Crèvecœur et al. BMC Neuroscience 2013, 14:87 Page 4 of 10
http://www.biomedcentral.com/1471-2202/14/87
Figure 1 Immunofluorescence of SV2A, SV2B and SV2C in
mouse brain at post-natal day 7 (P7). Fluorescent images of SV2A,
SV2B and SV2C labeling in the hippocampus (H), olfactory bulb (BO)
and striatum at P7. Five animals per age were observed in sagittal
sections, 4 or 5 animals per age in coronal sections. Nuclei were
counterstained with DAPI (blue). Original magnification 40X.
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the one observed in the hilus of DG. In contrast, the SV2B
signal was not altered during this period both in CA1 and
in the hilus of DG. Finally, SV2C was not detected in the
hippocampus at these three ages but expression was con-
firmed in striatum (data not shown). Therefore, the results
obtained by quantified confocal microscopy for SV2A in
hippocampus did not support the decrease of SV2A which
was first suspected using a non-quantified approach.
Laser microdissection and quantitative Western blot
We further used quantitative western blot to determine
levels for SV2A and SV2B at P5, P7 and P10. Hippocam-
pus and olfactory bulbs were microdissected and proteins
were extracted, quantified and analyzed by western blot
using actin as reference for normalization between sam-
ples (Figure 2B). Both SV2A and SV2B expression in-
creased between P5 and P7 in the entire hippocampus and
remained stable between P7 and P10. In contrast, SV2A
and SV2B expression in olfactory bulbs remained constant
between P5 and P7 but significantly increased between P7
and P10. SV2C was expressed at very low level in hippo-
campus (data not shown) and olfactory bulbs (Figure 2B).
In the striatum, where this isoform is highly abundant, anincrease was observed between P7 and P10. These data
correlated with the results obtained using qRT-PCR on
mRNA extracted from hippocampus: SV2A mRNA levels
expressed in the hippocampus showed a significant in-
crease between P5 and P7 and P10 respectively. Similarly
a significant increase of SV2B mRNA level was detected in
the hippocampus at P10 and P7 relative to mRNA quanti-
fied at P5. In contrast, the SV2C mRNA expression was
not altered and remained stable albeit at a substantially
lower level relative to SV2A and SV2B at all time points
(Figure 2C). Protein levels measured by western blot and
mRNA data analyzed by qPCR were consistent for major-
ity of time points and hippocampal sub-regions except for
the increase of SV2B mRNA levels in the whole hippo-
campus between P7 and P10 with only a limited increases
for SV2B protein expression in western blot.
To quantitatively assess expression of SV2 isoforms at
P5, P7 and P10 in CA1 and hilus of DG of the hippocam-
pus, laser-microdissection was performed. The proteins
were extracted and western blotting signals were quanti-
fied (Figure 3). Using quantitative western blotting, we
confirmed that in the hilus of DG, SV2A expression in-
creased between P5 and P7 and between P7 and P10, al-
beit statistical not significant for the earlier timepoint. In
the CA1 region of the hippocampus, the intensity of
SV2A signal increased between P5 and P7 and remained
stable at P10. For SV2B, an increase of expressed protein
was detected in the hilus of DG between P5 and P7 and
between P7 and P10. In the CA1 region, SV2B protein
level increased between P5 and P10 but no significant dif-
ference between P5 and P7 as well as P7 and P10 was
detected.
Discussion
Our study focuses on the expression of the three SV2 pro-
tein isoforms in the mouse developing brain from embry-
onic day 12 (first differentiated neurons) to post-natal day
30 (P30). We analyzed several regions in the central ner-
vous system, focusing the analysis of the SV2 protein ex-
pression in telencephalic regions given the relationships of
SV2A with epilepsy. Interestingly, non quantitative im-
munofluorescence suggests a decrease of the SV2A signal
in the hippocampus around P7 which is precisely the age
at which epileptic seizures are observed in SV2A KO mice.
A decrease of the SV2A signal was also observed using this
semi-quantitative approach at P7 in various telencephalic
regions (sub-cortical nuclei and pallidum), including the
thalamus, as well the hypothalamus, the mesencephalon in
the pontic and the bulbar regions suggesting potentially a
technical reason for this reduction. However, this technical
problem is unlikely as the decreased SV2A signal at P7 was
not observed in other brain regions such as olfactory bulbs
or in the cortical grey matter. Interestingly, the growth of
all these telencephalic structures are characterized by a
Figure 2 Quantification of SV2 isoforms. A: Quantification of SV2A
and SV2B in mouse brain by confocal microscopy at P5, P7 and P10.
Quantification by confocal microscopy were perfomed by using
Olympus software F10 ASW, allowing to measure the intensity of SV2A
and SV2B compared to selected surface. Different regions were selected
for these measures: hippocampus, hilus of dentatus gyrus (HDG) and
CA1of mice at P5, P7 and P10. Three animals per age were used this
quantification. Data are presented as mean +/− SD and were analyzed
by ANOVA following a Student’s t test. * p < 0.05; **p < 0.01; ns: not
significant. B: Quantification of SV2A, SV2B and SV2C in mouse brain by
western blot. Fluorescent western blots analysis of SV2A, SV2B and SV2C
proteins were carried out on hippocampus, striatum and olfactory bulb
(BO) of mice at P5, P7 and P10. Three animals per age were used.
Quantification of these western blots was performed using software
Image Master 1D Elite. Data are presented as mean +/− SD and were
analyzed by ANOVA following a Student’s t test. * p < 0.05; **p < 0.01; ns:
not significant. C: Quantification of SV2A, SV2B and SV2C mRNA in
mouse hippocampus. mRNA expression levels were measured by
RT-qPCR and normalized to the housekeeping gene β-actin. Data were
analyzed by a one-way ANOVA followed by a Bonferroni’s Multiple
Comparison Test. Three animals per age were used this quantification.
This experiment was repeated once with three new animals per age.
* p < 0.05; **p < 0.01; ***p < 0.001; ns: not significant.
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place at that age [37]. For this reason, we performed a pre-
cise quantification of the SV2A protein and mRNA expres-
sion levels in various hippocampal regions around P7. This
precise quantification did not confirm the apparent reduc-
tion of SV2A at P7 observed by immunohistology. Simi-
larly, a systematic analysis of SV2B expression in various
brain regions by the same methodological approach gave
similar results: an apparent decreased expression of SV2B
in hippocampus around P7 (data not shown) which was
not confirmed by the quantitative SV2B expression mea-
surements. Thus, we believe that this decrease in SV2A
and in SV2B expression which is apparent for hippo-
campus, is a consequence of a phenomenon which is
not related to the SV2A or SV2B expression per se but
rather to the enlargement and growth of tissue as mye-
lin appears at that age in these various mouse brain re-
gions [37], potentially affecting the semi-quantitative
immunohistological read out suggesting a decrease in
SV2A or SV2B expression.
A more precise quantification of SV2A, SV2B and SV2C
in whole hippocampus showed an increase in the expres-
sion of SV2A and SV2B between P5 and P7, and a
stabilization between P7 and P10, while SV2C showed low
expression at P5, P7 and P10. Majority of the protein
quantification data were confirmed by mRNA measure-
ments using qPCR indicating elevated levels for SV2A and
SV2B at later stages except for SV2B mRNA which was in-
creased between P7 and P10. The increase of SV2A expres-
sion in the hippocampus observed by confocal microscopy
measurements, between P5 and P7 seems to be restricted
exclusively to the CA1 region. Indeed, we confirmed a
Figure 3 Quantification of SV2A and SV2B by western blots in laser micro-dissection hippocampal regions. Fluorescent western blot
analysis of SV2A and SV2B proteins were carried out on the hilus of dentatus gyrus (HDG) and the CA1 region laser micro-dissected from the
hippocampus of mice at P5, P7 and P10. Three animals per age were used this quantification. This experiment was repeated once with three new
animals per age. The quantification was performed using software Image Master 1D Elite. Data are presented as mean +/− SD and were analyzed
by a ANOVA following a Student’s t test. * p < 0.05; **p < 0.01; ns: not significant.
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laser micro-dissection. The SV2A expression in hippocam-
pus is thus different than the SV2B expression which pro-
gressively increases in CA1. An observation that could
possibly explain that the absence of SV2A in KO mice at
that age is followed by onset of epileptic seizures onset,
while the absence of SV2B has no effect on seizure suscep-
tibility [38,39]. In this context, as presynaptic calcium regu-
lation by SV2 proteins have been hypothesized by studying
SV2B KO mice, the question of the exact role of SV2A, the
target of the anti epileptic drug levetiracetam, however re-
mains despite intense research elusive.
We thus observed a sharp increase of SV2A expression
in CA1 region at P7, the age of onset of epileptic seizures
in SV2A KO animals [17]. SV2A is expressed as early as
neurons differentiated, the question of the appearance of
seizures only at a late developmental stage has to be
addressed. On the other hand, the role of SV2A in seizure
susceptibility could be linked to its presence in inhibitory
neurons. When the seizures appear, GABA is changing
from being an excitatory to an inhibitory transmitter [40].
It was previously described, that P7 is the earliest develop-
mental stage where a long-term potentiation in CA1region in rats can be demonstrated suggesting an increase
of synaptic plasticity at that age [41]. More recently, it has
been demonstrated that levetiracetam controls more effi-
ciently epileptic seizures when SV2A is highly expressed
in tissue surrounding resected glioma [42]. This observa-
tion together with our study suggests that a high level of
SV2A expression is required to protect animals from epi-
leptic seizures and for the efficacy of levetiracetam. This
conclusion is consistent with the observation that SV2A
(+/−) heterozygous mice are more prone to seizures in a
range of various acute models as well as accelerated
epileptogenesis [43,44]. Starting at P7, an age character-
ized by myelinogenesis in several telencephalic regions
and by synaptic plasticity in CA1 region, a minimum
SV2A level is required to protect animals from seizures.
This potential “protective” effect of SV2A increased ex-
pression in CA1 at P7 is not compensate by SV2B either
because SV2A exhibit specific function(s) different to
SV2B or because SV2B expression does not increase in
hippocampus at the same age. In this context, it can be
speculated that levetiracetam could potentially increase
the SV2A activity, whatever this activity is and conse-
quently, thereby decreasing epileptic seizures. This
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observation that brivaracetam, a compound which binds
SV2A with a higher affinity than levetiracetam, exhibits
more potent anticonvulsant properties in various acute
epilepsy models [45].
Conclusions
In this work, we study the pattern of SV2 isoforms
expression during mouse brain development. By non-
quantitative and quantitative approaches, we show an in-
creased expression of SV2A restricted to the CA1 region
at P7. These findings provide new elements to better
understand the role of SV2A in the epileptic seizures.
Methods
Animals
In this study, we used mice (BALB/c) at different ages. Val-
idation of SV2A, SV2B and SV2C antibodies were
performed on SV2A KO, SV2B KO and SV2C KO mice.
The SV2C KO mice were generated in UCB (UCB Pharma
SA, Braine l’Alleud). Double SV2A/SV2B KO mice were
purchased from Jackson® Laboratory (Bar Harbor, Maine
USA) [17]. Animal care was in accordance with the declar-
ation of Helsinki and followed the guidelines of the Belgium
ministry of agriculture in agreement with European Com-
munity laboratory animal care and use regulation (86/609/
CEE, CE of J n°L358, 18 December 1986). Experimental
researchs on animals were performed with the approval of
ethics committee of the University of Liège. The number of
the file from ethics committee is 1122 and accepted
December 21, 2010.
Numbers of animals
Regarding the results presented in the section entitled
“Immunohistofluorescence (non quantitative)”, 5 animals
per age were observed in sagittal sections, 4 or 5 animals
per age in coronal sections. For the section entitled “Quan-
titative confocal immunofluorescence” 3 animals per age
were used (Figure 2A). For the section entitled “Laser mi-
cro dissection and quantitative Western blot” (Figure 2B),
3 animals per age were used. In the Figure 2C and Figure 3,
3 animals per age were used this quantification. This
experiment was repeated once with three new animals
per age.
Processing of tissue and sections
Mice were anaesthetized with a Nembutal® injection
(Pentobarbital 60mg, Ceva Sante Animal®, Bruxelles,
Belgium) before intracardiac perfusion with NaCl 0.9%
(VWR International®, Prolabo), followed by paraformalde-
hyde (PAF) 4% (4.3g/l NaOH, 44g/l paraformaldehyde,
18.8 g/l NaH2PO4) at 4°C. Brains were removed and
postfixed in PAF 4% at 4°C over night (o/n), then
cryoprotected for 48h in azide phosphate buffer saline(PBS) solution containing 30% sucrose before freezing
at −80°C in a 2-methylbutane solution (Aldrich®, Germany).
Forty micrometer thick coronal and sagittal sections were
cut on a cryostat and stored at −20°C.
Immunolabelling and histology
Permeabilization and blocking of unspecific binding sites
were performed by incubation at room temperature (RT)
during 30 min in the blocking solution (10% donkey serum
and 0.3% Triton X-100 in phosphate buffer saline, PBS).
Primary antibodies were diluted in a solution containing
10% donkey serum (Jackson Immunoresearch Laborator-
ies®, West Grove, PA, USA) and 0.1% Triton X-100 in PBS
(carrier solution). Commercially available antibodies di-
rected against SV2A (1:200, Abcam®, Cambridge, UK),
SV2B (1:500, SYSY®, Göttingen, Germany) and SV2C
(1:500, SYSY®) were used. Brain sections or fixed cells were
incubated with primary antibodies at RT for 2h or at 4°C
o/n. Three 15 min washes were performed in PBS at RT.
rhodamine-Red-X or RRX-conjugated secondary anti-
bodies were used (Jackson Immunoresearch Laboratories®).
All secondary antibodies were diluted 1:500 in the carrier
solution. Finally, tissue sections were washed three times
with PBS and coverslip added using DAPI-containing
Vectashield® solution (Hard Set Mounting Medium®, Vec-
tor laboratory, Burlingame, CA, USA). The slides were
stored in the dark at 4°C. Selectivity was confirmed by ab-
sence of staining on slices from SV2A KO, SV2B KO and
SV2C KO mice. In addition, the specificity of the anti-
bodies was confirmed by blocking peptides (Abcam® for
SV2A peptide and SYSY® for SV2B and SV2C peptides).
Incubation in absence of primary antibody resulted in a
complete loss of detectable signal.
Image acquisition data analysis
Immunostained sections were examined using the Olympus
Fluoview FV1000 confocal microscope (Olympus®
Europa, GmbH, Hamburg, Germany). The level of
immunohistofluorescence was semi-quantitatively as-
sessed based on the signal intensity and scored in four
classes (no labelling, low, medium and intense fluores-
cence and brightness) by two independent blinded ob-
servers. The quantification by confocal microscopy
was performed using Olympus software F10 ASW.
Western blotting
Non-fixed mouse brain was cut using a vibratome (Leica-
microsystems®, Grand-Bigard, Belgium) to obtain slices.
The microdissection of the slices were used to dissect re-
gion of interest in the hippocampus. Protein extraction
was performed on whole tissue using lysis buffer (Triton
X-100, PBS 0.1 M, NaCl 1.5 M, EDTA 0.5 M). After incu-
bation for 15 min on ice, the lysate was centrifuged for 10
min at 4°C at 10 000 G. Supernatant was collected and
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luted in loading buffer (Tris 106 mM, Tris base 141 mM,
LDS 2%, Glycerol 10%, EDTA 0,51 mM, SERVA Blue G250
0.22 mM and red Phenol 0.175 mM, pH: 8.5) and boiled
for 5 min. Microdissected hippocampus were directly
added to the loading buffer and incubated for 30 min in an
ultrasonic bath. Samples were then boiled for 10 min. Pro-
teins were separated using a 10% polyacrylamide commer-
cial gel (NuPage®, Invitrogen®, Merelbeke, Belgium) for 55
min at 200 volts (buffer: MOPS 50 mM, Tris Base 50 mM,
SDS 0.1% and EDTA 1 mM, pH: 7.7) and transferred on a
PVDF membrane (Roche®, Basel, Switzerland) for 60 min at
30 volts (buffer: Bicine 50 mM, Tris Base 50 mM and SDS
0.1%, pH 8.24). Membrane blocking was performed by in-
cubation for 1 h in a blocking solution (0.2% I-Block in
PBS-Tween, Tropix®). Then, the membranes were incu-
bated for 2 h at RT in the presence of primary antibody di-
rected against SV2A (1:2000, Abcam®), SV2B (1:10000,
SYSY®) or SV2C (1:5000, SYSY®). After three washing steps
in PBS-Tween solution (Tris 50mM, NaCl 120mM and
Tween 0.2%, pH 7.6), the membranes were incubated for
1h with a secondary fluorescent antibody (Cy-5 conjugated
anti-rabbit IgG, Jackson Immunoresearch Laboratories®) at
RT. After three additional washes, the membranes were
incubated at 37°C for 1 h in the dark in SuperSignal West
Pico Chemiluminescent Substrate (Thermo Fisher Scien-
tific®, Erembodegem, Belgium). Western blots were revealed
using typhoon 9400 (Amersham Pharmacia Biotech®, GE
Healthcare Lifesciences, Diegem, Belgium). The quantifica-
tion of western blots was performed by Image Master 1D
Elite software (Amersham Pharmacia Biotech®, GE
Healthcare Lifesciences).RNA purification and quantification
RNA extraction was performed with the RNeasy (Qiagen®,
Venlo, Netherlands). One μg of total RNA was used to
synthesize cDNA with the Applied Biosystems high cap-
acity cDNA reverse transcription kit in a total volume of
100 μl following the manufacturer’s protocol (Life Tech-
nologies Corporation®, Carlsbad, California). Taqman
Real-Time Quantitative PCR reactions (qPCR) were per-
formed with the ABI 7900HT Sequence Detection System.
Undiluted, 10× and 100× diluted cDNA were analyzed in
duplicate for SV2A, SV2B and SV2C expression, using in-
ventoried (SV2A and SV2B) and made to order (SV2C)
Applied Biosystems TaqMan gene expression assays. Cq
values were obtained (Applied Biosystems® SDS 2.3 soft-
ware) using automatic threshold and baseline. To nor-
malize the Cq values to the amount of cDNA per well
(ΔCq), mouse β-actin was used as endogenous control.
Relative gene expression was calculated with the formula
2–ΔΔCq [46], with the mean of the ΔCq of the P5 samples
as calibrator to obtain the ΔCq.Statistical analysis
All numerical analysis were performed using GraphPad
Prism software. Statistical analysis was performed using
two-way analysis of variance (ANOVA) followed by a Stu-
dent’s t post-test. Data are presented as mean with standard
deviation of mean (Mean +/− SD). p value < 0,05 was con-
sidered significant. For qPCR: One-way ANOVA followed
by a Bonferroni’s Multiple Comparison Test was used.
Additional files
Additional file 1: Validation of antibodies anti- SV2A, SV2B, SV2C
on WT,SV2A KO (SV2A−/−) and SV2B KO (SV2B−/−) mice at P7.
Representative fluorescence images of SV2A, SV2B and SV2C
labelling in the hippocampus (H) of WT, SV2A KO (SV2A−/−) and
SV2B KO (SV2B−/−) mice at P7. Nuclei were counterstained with
DAPI (blue). Original magnification 40X.
Additional file 2: Validation of antibodies anti- SV2A, SV2B, SV2C
on SV2A KO (SV2A−/−) mice and using blocking peptide. Fluorescent
images of SV2A labelling in the hippocampus (H) of WT, SV2A KO
(heterozygous) or SV2A KO (homozygous) mice. For SV2B and SV2C,
blocking peptides were used at different concentration (1 ng/mL; 10 ng/mL;
100 ng/mL; 1000 ng/mL). Nuclei were counterstained with DAPI (blue).
Substantia Nigra (SN). Original magnification 40X.
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